The Analysis of Features of Realization of Regional Programs of Preferential Provision of Medicines in Some Territorial Subjects of the Russian Federation Depending on Categories of Diseases

Петрухина, И. К.; Egorova, A.V.; Loginova, L.V.; Bubnova, A.A.

doi:10.30809/solo.2.2019.27

SOLO

2019

DOI: 10.30809/solo.2.2019.27

|View full text |Cite

The Analysis of Features of Realization of Regional Programs of Preferential Provision of Medicines in Some Territorial Subjects of the Russian Federation Depending on Categories of Diseases

И. К. Петрухина¹,

A.V. Egorova²,

L.V. Loginova³

et al.

Abstract: Ñîâðåìåííàÿ îðãàíèçàöèÿ ëåêàðñòâåííîãî îáåñïå÷åíèÿ ¹ 2/2019 Редакционная коллегия Editorial board Ягудина Роза Исмаиловна Главный редактор, Заведующий кафедрой организации лекарственного обеспечения и фармакоэкономики Первого Московского государственного медицинского университета им. И.М. Сеченова, профессор, д.ф.н

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

2023

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Analysis of drug provision for patients with broncho-obstructive diseases in the Russian Federation

Avdeev,

Linnik,

Tumenko

2023

jour

View full text Add to dashboard Cite

Introduction. The article presents data from an analysis of drug provision for patients with bronchial asthma and chronic obstructive pulmonary disease, both in inpatient conditions and at the stage of outpatient treatment. The object of the study was the provision of medications to patients with broncho-obstructive diseases in the constituent entities of the Russian Federation. The purpose of our study was to study drug provision for patients with broncho-obstructive diseases. Why the following research methods were used: purchases of medicines in federal districts and some constituent entities of the Russian Federation in 2019–2022 were analyzed, the amount of funds per patient diagnosed with bronchial asthma or chronic obstructive pulmonary disease was calculated. Separately, we analyzed the purchases of short- and long-acting bronchodilators, as well as mono- and combination drugs and monoclonal antibody drugs for the treatment of patients with bronchial asthma. Data on drug purchases were analyzed using the website zakupki.gov.ru; information on the number of patients in federal districts and constituent entities of the Russian Federation was taken from statistical materials of the Russian Ministry of Health. Results. We found a multiple difference between federal districts in the amount of funds per patient in both 2019 and 2022, and differentiation between federal districts also turned out to be the case when analyzing preferential drug coverage. The dynamics of the amounts of funds spent by entities on the purchase of drugs for the treatment of patients in outpatient settings turned out to be multidirectional: some entities not only did not increase these amounts in 2012 compared to 2019, but, on the contrary, decreased them. At the same time, the difference between the subjects of the same federal district reaches tenfold values. Conclusion. Patients with broncho-obstructive diseases living in different federal districts of the country have different drug coverage both in outpatient and inpatient treatment settings. To improve the drug supply for these patients, it is necessary to introduce a unified methodology for calculating the planned need for drugs and oblige the subjects to provide patients with chronic obstructive pulmonary disease with drugs at the expense of the budgets of the subjects.

show abstract

Analysis of drug provision for patients with broncho-obstructive diseases in the Russian Federation

Avdeev,

Linnik,

Tumenko

2023

jour

View full text Add to dashboard Cite

show abstract

Analysis of the correspondence of the lists of drugs for cancer patients' treatment included in the territorial programs of state guarantees to the list of vital and essential drugs

Zudin

Linnik

Александрова

2021

Zdravoohran. Ross. Fed.

View full text Add to dashboard Cite

The aim of the study was to study the compliance of the list of drugs for the treatment of malignant neoplasms in the territorial state guarantee programs (TSGP) with the list of vital and essential drugs (VED) in the constituent entities of the Russian Federation and the practice of purchasing drugs at the expense of regional preferential provision (RPP) funds. Material and methods. The analyzed territorial programs of state guarantees were compared with the list of drugs for RPP for the patients with malignant neoplasms with the VED. An assessment of medication procurement in 2019 and 2020 was carried out and compared with the current list of RLO in all constituent entities of the Russian Federation. Results. Only 14% of the Russian Federation regions in 2019 and 20% in 2020 met the territorial state program of guarantees requirement. The average number of medications included in the territorial state program of guarantees was 73 INNs in 2019 and 100 INNs in 2020. The number of regions with a complete list of drugs accounted for 7% to 33% in the corresponding Federal Districts. In 2020 the number of regions with a complete list of medications in a territorial program of state guarantees did not change. Discussion. Reduction of medications from the VED purchased at the expense of RPP reduces the number of possible treatment regimens, and limits oncologists’ ability to provide care on an outpatient basis. Conclusion. Most Russian Federation regions violate the requirements of the territorial program of state guarantees do not harmonize the list of medications in the Program with EDL. The practice of purchasing medications from the territorial program of state guarantees indicates the absence of finance mechanisms for providing medications to patients at the outpatient stage of treatment.

show abstract

Analysis of the accessibility of cancer patients to drug provision at the outpatient stage of treatment in the Russian Federation

Linnik

2023

Zdravoohran. Ross. Fed.

View full text Add to dashboard Cite

Introduction. The outpatient stage of management of patients with malignant neoplasms does not have additional funding. Availability of patients to prescribed drugs on outpatient review of funds allocated by the Russian Federation for the purchase of drugs based upon budgets providing for benefits. In connection with the study of the problem of procurement of drugs for the treatment of patients with malignant neoplasms in outpatient treatment, an urgent task arises, the solution of which is the essence of the development of a study on the planning of drug treatment of patients. Purpose is to study the accessibility of patients with malignant neoplasms to drug provision at the outpatient stage of treatment in the Federal Districts of the Russian Federation. Material and methods. To study the availability of patients with malignant neoplasms, the supply of medicines for the treatment of patients with malignant neoplasms in 2019 and 2020 to hospitals purchased at the expense of the constituent entities of the Russian Federation and the federal budget in the Federal Districts was analyzed. We compared the funds spent between the subjects of the Russian Federation in terms of patients with a first diagnosis. To compare the provision of patients with drugs, we recalculated the amount of funds spent on the purchase of drugs per patient with a newly diagnosed oncological disease living in the Federal District. Results. Significant differences were found in the provision between the Federal Districts, reaching almost four times the size. Limitations. When studying the accessibility of patients with malignant neoplasms to drug provision at the outpatient stage of treatment, purchases of all Federal Districts of the Russian Federation at the expense of both the subjects of the Russian Federation and the federal budget were analyzed, which is a sufficient reference sample. Conclusion. A significant difference in the amount allocated per patient both from the funds of the regional and federal budgets, with the newly diagnosed malignant neoplasm in the Federal Districts creates unequal conditions for treating patients on an outpatient basis.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

The Analysis of Features of Realization of Regional Programs of Preferential Provision of Medicines in Some Territorial Subjects of the Russian Federation Depending on Categories of Diseases

Cited by 3 publications

References 0 publications

Analysis of drug provision for patients with broncho-obstructive diseases in the Russian Federation

Analysis of drug provision for patients with broncho-obstructive diseases in the Russian Federation

Analysis of the correspondence of the lists of drugs for cancer patients' treatment included in the territorial programs of state guarantees to the list of vital and essential drugs

Analysis of the accessibility of cancer patients to drug provision at the outpatient stage of treatment in the Russian Federation

Contact Info

Product

Resources

About